[{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"ec924f14-828b-407b-8c51-af2c2883b940","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415475","created_at":"2023-11-14T16:14:28.256Z","updated_at":"2024-07-02T16:35:24.610Z","phase":"Phase 1","brief_title":"Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05415475","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 09/15/2024","primary_completion_date":" 09/15/2024","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2024-01-04"},{"id":"9b7d28f1-9100-4935-af40-c1881d67e712","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010862","created_at":"2023-08-25T15:08:21.013Z","updated_at":"2024-07-02T16:35:29.975Z","phase":"Phase 1","brief_title":"Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT06010862","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CEACAM5 positive","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-11-08"},{"id":"30b7368a-f8fa-42a9-b19a-c1d96001eccd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00499083","created_at":"2021-01-18T01:47:11.312Z","updated_at":"2024-07-02T16:35:35.156Z","phase":"Phase 2","brief_title":"Paclitaxel, Cyclophosphamide \u0026 Doxorubicin, Autologous Dendritic Cells \u0026 Surgery in Stage II/III Breast Cancer (Women)","source_id_and_acronym":"NCT00499083","lead_sponsor":"University of Nebraska","biomarkers":" HER-2 • CEACAM5 • PTGS2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression","tags":["HER-2 • CEACAM5 • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • tamoxifen • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Soltamox (tamoxifen citrate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 01/28/2010","study_completion_date":" 01/28/2010","last_update_posted":"2023-09-29"},{"id":"435ca39e-0679-4ca6-8e02-440b79b5541f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043466","created_at":"2023-09-21T15:10:27.528Z","updated_at":"2024-07-02T16:35:36.621Z","phase":"Phase 1","brief_title":"A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT06043466","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive","tags":["PD-L1 • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-09-21"},{"id":"a9351bab-0b8f-46be-8127-567aa4f402a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04405557","created_at":"2021-01-18T21:15:01.733Z","updated_at":"2024-07-02T16:35:47.050Z","phase":"","brief_title":"The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor","source_id_and_acronym":"NCT04405557","lead_sponsor":"Geneplus-Beijing Co. Ltd.","biomarkers":" MUC16","pipe":" | ","alterations":" CEACAM5 positive","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 757","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 01/16/2022","primary_completion_date":" 01/16/2022","study_txt":" Completion: 01/16/2025","study_completion_date":" 01/16/2025","last_update_posted":"2023-05-26"},{"id":"57ba0d45-7caa-46e6-b460-70042994b802","acronym":"","url":"https://clinicaltrials.gov/study/NCT04348643","created_at":"2021-01-18T21:02:17.249Z","updated_at":"2024-07-02T16:35:50.385Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer","source_id_and_acronym":"NCT04348643","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6","pipe":" | ","alterations":" CEACAM5 positive","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-04-18"},{"id":"2970cc81-805c-417e-8aae-d4e7ccdaa0c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02587247","created_at":"2021-01-18T12:33:08.299Z","updated_at":"2024-07-02T16:36:06.688Z","phase":"Phase 2","brief_title":"ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer","source_id_and_acronym":"NCT02587247","lead_sponsor":"Nantes University Hospital","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TF2"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2022-07-26"},{"id":"747d980f-510f-40da-b6a6-75b385ef0c32","acronym":"","url":"https://clinicaltrials.gov/study/NCT00924092","created_at":"2021-01-18T03:34:44.186Z","updated_at":"2024-07-02T16:36:52.606Z","phase":"Phase 1","brief_title":"An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...","source_id_and_acronym":"NCT00924092","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CEACAM5 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GI-6207"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/13/2009","start_date":" 03/13/2009","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 08/02/2012","study_completion_date":" 08/02/2012","last_update_posted":"2019-12-12"},{"id":"de8b242f-ed89-4f3f-8916-b4ebe9a2fdf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02959151","created_at":"2021-01-29T07:13:42.484Z","updated_at":"2024-07-02T16:37:27.688Z","phase":"Phase 1/2","brief_title":"A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy","source_id_and_acronym":"NCT02959151","lead_sponsor":"Shanghai GeneChem Co., Ltd.","biomarkers":" MSLN • GPC3","pipe":" | ","alterations":" CEACAM5 positive","tags":["MSLN • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2016-11-08"},{"id":"96ed0478-102e-4b80-9602-ad596e7b15a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01221675","created_at":"2021-01-18T04:54:28.690Z","updated_at":"2024-07-02T16:37:29.423Z","phase":"Phase 1/2","brief_title":"TF2- Small Cell Lung Cancer Radio Immunotherapy","source_id_and_acronym":"NCT01221675","lead_sponsor":"Centre René Gauducheau","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • CEACAM5 positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TF2"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-08-31"}]